Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma.
暂无分享,去创建一个
[1] Poul Erik Petersen,et al. Oral Cancer Prevention and Control – the Approach of the World Health Organization , 2022 .
[2] T. Rosol,et al. Animal models of head and neck squamous cell carcinoma. , 2016, Veterinary journal.
[3] R. Coletta,et al. In vivo and in vitro effects of curcumin on head and neck carcinoma: a systematic review , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[4] E. Mroz,et al. Intra-tumor heterogeneity in head and neck cancer and its clinical implications , 2016, World journal of otorhinolaryngology - head and neck surgery.
[5] B. Aggarwal,et al. Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. , 2017, Clinical science.
[6] N. Magné,et al. Preclinical models in HNSCC: A comprehensive review. , 2017, Oral oncology.
[7] Hong-gang Yu,et al. CD24 blunts oral squamous cancer development and dampens the functional expansion of myeloid-derived suppressor cells , 2016, Oncoimmunology.
[8] Fazli Wahid,et al. Curcumin in Cancer Chemoprevention: Molecular Targets, Pharmacokinetics, Bioavailability, and Clinical Trials , 2010, Archiv der Pharmazie.
[9] G. Garlet,et al. Relevance of CCL3/CCR5 axis in oral carcinogenesis , 2017, Oncotarget.
[10] J. Weiss,et al. Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/αCD40 Therapy , 2014, The Journal of Immunology.
[11] S. Strome,et al. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. , 2014, Oral oncology.
[12] Fu-Tsai Chung,et al. Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer , 2009, Journal of Cancer Research and Clinical Oncology.
[13] J. Califano,et al. Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2014, Clinical Cancer Research.
[14] A. Kulkarni,et al. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC , 2017, Journal of dental research.
[15] Miao-Fen Chen,et al. Inflammation‐induced myeloid‐derived suppressor cells associated with squamous cell carcinoma of the head and neck , 2017, Head & neck.
[16] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[17] Jianjiang Zhao,et al. Increased frequency of CD4+ CD25+ FOXP3+ cells correlates with the progression of 4-nitroquinoline1-oxide-induced rat tongue carcinogenesis , 2013, Clinical Oral Investigations.
[18] N. Kosaka,et al. The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[19] Y. Su,et al. Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice. , 2012, Oral diseases.
[20] Jennifer R. Grandis,et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.
[21] G. Kristiansen,et al. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma , 2017, Oncotarget.
[22] S. Agelaki,et al. The promise of immunotherapy in head and neck squamous cell carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] C. Jiang,et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Mohammad Reza Zamani,et al. PD-1 and cancer: molecular mechanisms and polymorphisms , 2017, Immunogenetics.
[25] Z. Qin,et al. Transmembrane TNF-α Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2 , 2014, The Journal of Immunology.
[26] M. Manjili,et al. Role of Tregs in Cancer Dormancy or Recurrence , 2016, Immunological investigations.
[27] K. Tanaka,et al. Xeroderma pigmentosum group A gene action as a protection factor against 4-nitroquinoline 1-oxide-induced tongue carcinogenesis. , 2001, Carcinogenesis.
[28] H. Harada,et al. Clinical Course of Oral Squamous Cell Carcinoma in Patients on Immunosuppressant and Glucocorticoid Therapy. , 2017, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[29] O. Stasikowska-Kanicka,et al. Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma , 2017, Pathology & Oncology Research.
[30] I. Durán,et al. Biomarkers of response to PD-1/PD-L1 inhibition. , 2017, Critical reviews in oncology/hematology.
[31] D. Gabrilovich,et al. Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.
[32] A. Chinnaiyan,et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression , 2018, The Journal of clinical investigation.